D
David B. Duignan
Researcher at Pfizer
Publications - 20
Citations - 1253
David B. Duignan is an academic researcher from Pfizer. The author has contributed to research in topics: Efflux & In vivo. The author has an hindex of 17, co-authored 20 publications receiving 1160 citations.
Papers
More filters
Journal ArticleDOI
Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport.
TL;DR: The use of cryopreserved human hepatocytes in 24-well sandwich culture to form intact bile canaliculi and to exhibit functional uptake and efflux transport has been successfully demonstrated.
Journal ArticleDOI
Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites
TL;DR: A novel micropatterned hepatocyte coculture system was evaluated for its ability to generate human in vivo metabolites and it is suggested that this in vitro system offers the highest performance among in vitro metabolism systems to predict major human in vitro metabolites.
Journal ArticleDOI
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
Jeffrey A. Pfefferkorn,Angel Guzman-Perez,John Litchfield,Robert J. Aiello,Judith L. Treadway,John C. Pettersen,Martha L. Minich,Kevin J. Filipski,Christopher S. Jones,Meihua Tu,Gary Erik Aspnes,Hud Lawrence Risley,Jianwei Bian,Benjamin D. Stevens,Patricia Bourassa,Theresa D’Aquila,Levenia Baker,Nicole Barucci,Alan Robertson,Francis Bourbonais,David R. Derksen,Margit MacDougall,Over Cabrera,Jing Chen,Amanda L. Lapworth,James A. Landro,William J. Zavadoski,Karen Atkinson,Nahor Haddish-Berhane,Beijing Tan,Lili Yao,Rachel E. Kosa,Manthena V.S. Varma,Bo Feng,David B. Duignan,Ayman El-Kattan,Sharad B. Murdande,Shenping Liu,Mark Ammirati,John D. Knafels,Paul DaSilva-Jardine,Laurel Sweet,Spiros Liras,Timothy P. Rolph +43 more
TL;DR: 19 is identified as a potent glucokinase activator with a greater than 50-fold liver-to-pancreas ratio of tissue distribution in rodent and non-rodent species, leading to its selection as a clinical development candidate for treating type 2 diabetes.
Journal ArticleDOI
Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships.
TL;DR: QSPKR models were successfully developed for biliary excretion of non-congeneric compounds in rats and humans, providing a quantitative prediction of biliary clearance of compounds.
Journal ArticleDOI
pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.
Manthena V.S. Varma,Charles J. Rotter,Jonathan Chupka,Kevin M. Whalen,David B. Duignan,Bo Feng,John Litchfield,Theunis C. Goosen,Ayman El-Kattan +8 more
TL;DR: It is noted that OATP2B1-mediated transport of E-3-S, but not rosuvastatin, is pH sensitive in intestinal epithelial (Caco-2) cells, and uptake at acidic pH was diminished in the presence of proton ionophore, suggesting proton gradient as the driving force for O ATP2 B1 activity.